RSV shots in the birth hospital: why coverage is still a fight this season

RSV is the winter virus that fills pediatric wards. For the last two seasons the United States has had tools that did not exist for most of this century: a maternal vaccine in pregnancy, and a long-acting antibody (nirsevimab and related products) given to infants. The American Academy of Pediatrics spent mid-September 2026 warning that too many newborns still leave the hospital unprotected because the shot is expensive and insurers have not settled how to pay hospitals for it.

## Background
RSV is ordinary for older children and hard for the youngest. Most healthy infants who catch it have a cold. A slice get bronchiolitis, need oxygen, or end up in intensive care. Before the new products, the only monoclonal antibody (palivizumab) was reserved for the tiniest, highest-risk preemies and required monthly doses.

The new strategy is simpler on paper: protect the baby before the first RSV exposure, ideally before discharge from the birth hospital. That is the same logic as hepatitis B vaccine at birth. The difference is price and billing. Hospitals buy the product up front. Many payers still treat it as a pediatric-office benefit, not an inpatient drug.

## What changed this week
AAP News (14 September 2026) reported that hospitals are hitting two walls as RSV season approaches in much of the country: the acquisition cost of infant RSV immunization, and the lack of a clean payment structure from insurers. The Academy is pushing for immunization before discharge rather than waiting for a first well-child visit — a visit that can slip, especially for families without a booked pediatrician.

That is the development that matters this week. The science is not new. The bottleneck is logistics and money.

## Competing viewpoints
Pediatric groups argue the birth hospital is the only guaranteed touchpoint. Miss it, and a baby born in September may see RSV in October before a clinic appointment.

Hospital finance teams argue they cannot stock a high-cost specialty product if reimbursement is delayed or denied. Some systems limit doses to Medicaid or “highest risk only,” which undercuts the original population-level plan.

Insurers point to existing outpatient coverage and prefer the pediatric office, where inventory and counseling already live.

Public-health voices note that maternal vaccination during pregnancy covers some infants and should not be forgotten in the hospital-billing fight — but it does not cover every birth, and timing of the maternal dose matters.

## What to watch next
- Whether state Medicaid programs and large commercial plans publish an inpatient RSV-antibody billing code and rate before peak season.
- Hospital policies: universal offer vs risk-stratified stock.
- Uptake data for maternal RSV vaccine vs infant antibody this fall.
- Any CDC or AAP season-timing update if southern states see RSV earlier than the rest of the country.

## What parents can do today
1. If you are still pregnant, ask your obstetric clinician about maternal RSV vaccine timing.
2. If you are packing a hospital bag, put “RSV antibody before discharge?” on the question list next to vitamin K and hepatitis B.
3. If you already went home without it, call the pediatric office this week. Do not wait for a “when you have time” visit.
4. Insurance scripts help: ask whether the product is covered as a medical benefit in the hospital, and what the out-of-pocket is.
5. RSV hygiene still counts: wash hands, keep obviously sick visitors away from a newborn in the first months.

This is not medical advice. Your baby’s clinician knows the local RSV pattern and which product is in stock.

Source: AAP News, “Lack of insurance coverage for RSV immunization in hospitals leaves newborns unprotected,” 14 September 2026.